Silence Therapeutics Statistics
Share Statistics
Silence Therapeutics has 47.23M
shares outstanding. The number of shares has increased by 204.18%
in one year.
| Shares Outstanding | 47.23M |
| Shares Change (YoY) | 204.18% |
| Shares Change (QoQ) | 200.06% |
| Owned by Institutions (%) | 17.68% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 18,117 |
| FTD / Avg. Volume | 7.91% |
Short Selling Information
The latest short interest is 1.25M, so 2.65% of the outstanding
shares have been sold short.
| Short Interest | 1.25M |
| Short % of Shares Out | 2.65% |
| Short % of Float | 3.35% |
| Short Ratio (days to cover) | 5.9 |
Valuation Ratios
The PE ratio is -7.17 and the forward
PE ratio is -10.25.
Silence Therapeutics's PEG ratio is
0.44.
| PE Ratio | -7.17 |
| Forward PE | -10.25 |
| PS Ratio | 7.51 |
| Forward PS | 1.1 |
| PB Ratio | 2.42 |
| P/FCF Ratio | -4.79 |
| PEG Ratio | 0.44 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Silence Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.14,
with a Debt / Equity ratio of 0.
| Current Ratio | 11.14 |
| Quick Ratio | 11.14 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $372,913.79 |
| Profits Per Employee | $-390,594.83 |
| Employee Count | 116 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 845K |
| Effective Tax Rate | -1.9% |
Stock Price Statistics
The stock price has increased by -72.46% in the
last 52 weeks. The beta is 1.19, so Silence Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.19 |
| 52-Week Price Change | -72.46% |
| 50-Day Moving Average | 3.65 |
| 200-Day Moving Average | 9.41 |
| Relative Strength Index (RSI) | 74.79 |
| Average Volume (20 Days) | 229,145 |
Income Statement
In the last 12 months, Silence Therapeutics had revenue of 43.26M
and earned -45.31M
in profits. Earnings per share was -0.98.
| Revenue | 43.26M |
| Gross Profit | 31.45M |
| Operating Income | -63.32M |
| Net Income | -45.31M |
| EBITDA | -48.99M |
| EBIT | -49.58M |
| Earnings Per Share (EPS) | -0.98 |
Full Income StatementBalance Sheet
The company has 121.33M in cash and 117K in
debt, giving a net cash position of 121.21M.
| Cash & Cash Equivalents | 121.33M |
| Total Debt | 117K |
| Net Cash | 121.21M |
| Retained Earnings | -474.04M |
| Total Assets | 185.3M |
| Working Capital | 189.05M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -67.64M
and capital expenditures -211K, giving a free cash flow of -67.85M.
| Operating Cash Flow | -67.64M |
| Capital Expenditures | -211K |
| Free Cash Flow | -67.85M |
| FCF Per Share | -0.48 |
Full Cash Flow StatementMargins
Gross margin is 72.7%, with operating and profit margins of -146.38% and -104.74%.
| Gross Margin | 72.7% |
| Operating Margin | -146.38% |
| Pretax Margin | -102.79% |
| Profit Margin | -104.74% |
| EBITDA Margin | -113.25% |
| EBIT Margin | -146.38% |
| FCF Margin | -156.85% |
